Matches in SemOpenAlex for { <https://semopenalex.org/work/W631494967> ?p ?o ?g. }
- W631494967 endingPage "1503" @default.
- W631494967 startingPage "1494" @default.
- W631494967 abstract "Peptide-mediated targeting of tumors has become an effective strategy for cancer therapy. Retro-inverso peptides resist protease degradation and maintain their bioactivity. We used the retro-inverso peptide D(PRPSPKMGVSVS) (D-SP5) as a targeting ligand to develop gene therapy for gastric adenocarcinoma. D-SP5 has a higher affinity for human gastric adenocarcinoma (SGC7901) cells compared with that of its parental peptide, L(SVSVGMKPSPRP) (L-SP5). Polyethylenimine (PEI)/pDNA, polyethylene glycol (mPEG)-PEI/pDNA and D-SP5-PEG-PEI/pDNA were prepared for further study. Quantitative luciferase assays showed the transfection efficiency of D-SP5-PEG-PEI/pGL4.2 was larger compared with that of mPEG-PEI/pGL4.2. Flow cytometry assays revealed that the apoptosis rates of SGC7901 cells treated with D-SP5-PEG-PEI/pTRAIL were larger than mPEG-PEI/pTRAIL. Western blot assays indicated that the expression of tumor necrosis factor-related apoptosis inducing ligand (TRAIL) protein in SGC7901 cells treated with D-SP5-PEG-PEI/pTRAIL was higher compared with that in cells treated with mPEG-PEI/pTRAIL. In vivo pharmacodynamics study revealed that D-SP5-PEG-PEI/pTRAIL could inhibit the growth of gastric adenocarcinoma SGC7901 xenografts in nude mice. Our results demonstrate that D-SP5-PEG-PEI is a safe and efficient gene delivery vector with potential applications in antitumor gene therapy." @default.
- W631494967 created "2016-06-24" @default.
- W631494967 creator A5017353282 @default.
- W631494967 creator A5017651819 @default.
- W631494967 creator A5029632441 @default.
- W631494967 creator A5039667277 @default.
- W631494967 creator A5066565410 @default.
- W631494967 creator A5068565044 @default.
- W631494967 creator A5069973518 @default.
- W631494967 creator A5071437727 @default.
- W631494967 creator A5072438739 @default.
- W631494967 creator A5074004084 @default.
- W631494967 creator A5076407920 @default.
- W631494967 creator A5085067240 @default.
- W631494967 date "2015-06-23" @default.
- W631494967 modified "2023-10-16" @default.
- W631494967 title "D-SP5 Peptide-Modified Highly Branched Polyethylenimine for Gene Therapy of Gastric Adenocarcinoma" @default.
- W631494967 cites W1484817497 @default.
- W631494967 cites W1493750131 @default.
- W631494967 cites W163582340 @default.
- W631494967 cites W1966111129 @default.
- W631494967 cites W1969552295 @default.
- W631494967 cites W1974489757 @default.
- W631494967 cites W1987506447 @default.
- W631494967 cites W1995278782 @default.
- W631494967 cites W1995997091 @default.
- W631494967 cites W1998697301 @default.
- W631494967 cites W2000136129 @default.
- W631494967 cites W2003414091 @default.
- W631494967 cites W2009085926 @default.
- W631494967 cites W2014094604 @default.
- W631494967 cites W2029012405 @default.
- W631494967 cites W2030556927 @default.
- W631494967 cites W2036169673 @default.
- W631494967 cites W2039551908 @default.
- W631494967 cites W2041874034 @default.
- W631494967 cites W2048456201 @default.
- W631494967 cites W2050932091 @default.
- W631494967 cites W2051674776 @default.
- W631494967 cites W2051712296 @default.
- W631494967 cites W2062982150 @default.
- W631494967 cites W2069753162 @default.
- W631494967 cites W2074870430 @default.
- W631494967 cites W2077654655 @default.
- W631494967 cites W2079445254 @default.
- W631494967 cites W2083597639 @default.
- W631494967 cites W2086069830 @default.
- W631494967 cites W2087497808 @default.
- W631494967 cites W2088291142 @default.
- W631494967 cites W2091131912 @default.
- W631494967 cites W2092370740 @default.
- W631494967 cites W2092707316 @default.
- W631494967 cites W2100671145 @default.
- W631494967 cites W2101312385 @default.
- W631494967 cites W2107743746 @default.
- W631494967 cites W2130988210 @default.
- W631494967 cites W2142218823 @default.
- W631494967 cites W2145444317 @default.
- W631494967 cites W2312704188 @default.
- W631494967 cites W304669699 @default.
- W631494967 doi "https://doi.org/10.1021/acs.bioconjchem.5b00137" @default.
- W631494967 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26052814" @default.
- W631494967 hasPublicationYear "2015" @default.
- W631494967 type Work @default.
- W631494967 sameAs 631494967 @default.
- W631494967 citedByCount "18" @default.
- W631494967 countsByYear W6314949672015 @default.
- W631494967 countsByYear W6314949672016 @default.
- W631494967 countsByYear W6314949672018 @default.
- W631494967 countsByYear W6314949672019 @default.
- W631494967 countsByYear W6314949672020 @default.
- W631494967 countsByYear W6314949672021 @default.
- W631494967 countsByYear W6314949672022 @default.
- W631494967 countsByYear W6314949672023 @default.
- W631494967 crossrefType "journal-article" @default.
- W631494967 hasAuthorship W631494967A5017353282 @default.
- W631494967 hasAuthorship W631494967A5017651819 @default.
- W631494967 hasAuthorship W631494967A5029632441 @default.
- W631494967 hasAuthorship W631494967A5039667277 @default.
- W631494967 hasAuthorship W631494967A5066565410 @default.
- W631494967 hasAuthorship W631494967A5068565044 @default.
- W631494967 hasAuthorship W631494967A5069973518 @default.
- W631494967 hasAuthorship W631494967A5071437727 @default.
- W631494967 hasAuthorship W631494967A5072438739 @default.
- W631494967 hasAuthorship W631494967A5074004084 @default.
- W631494967 hasAuthorship W631494967A5076407920 @default.
- W631494967 hasAuthorship W631494967A5085067240 @default.
- W631494967 hasConcept C10138342 @default.
- W631494967 hasConcept C104317684 @default.
- W631494967 hasConcept C153911025 @default.
- W631494967 hasConcept C162324750 @default.
- W631494967 hasConcept C185592680 @default.
- W631494967 hasConcept C2775925850 @default.
- W631494967 hasConcept C54009773 @default.
- W631494967 hasConcept C54400483 @default.
- W631494967 hasConcept C55493867 @default.
- W631494967 hasConcept C86803240 @default.
- W631494967 hasConcept C98274493 @default.